Browsing by Author Assenat, Eric
Showing results 1 to 3 of 3
Issue Date | Title | Author(s) |
---|---|---|
13-Nov-2020 | Effect of ramucirumab on ALBI grade in patients with advanced HCC: Results from REACH and REACH-2 | Kudo, Masatoshi; Galle, Peter R.; Brandi, Giovanni; Kang, Yoon Koo; Yen, Chia Jui; Finn, Richard S.; Llovet i Bayer, Josep Maria; Assenat, Eric; Merle, Philippe; Chan, Stephen L.; Palmer, Daniel H.; Ikeda, Masafumi; Yamashita, Tatsuya; Vogel, Arndt; Huang, Yi Hsiang; Abada, Paolo; Yoshikawa, Reigetsu; Shinozaki, Kenta; Wang, Chunxiao; Widau, Ryan C.; Zhu, Andrew X. |
25-Jan-2017 | Objective response by mRECIST as a predictor and potential surrogate end point of overall survival in advanced HCC | Lencioni, Riccardo; Montal, Robert; Torre, Ferran; Park, Joong-Won; Decaens, Thomas; Raoul, Jean-Luc; Kudo, Masatoshi; Chang, Charissa Y.; Ríos, José; Boige, Valerie; Assenat, Eric; Kang, Yoon-Koo; Lim, Ho-Yeong; Walters, Ian; Llovet i Bayer, Josep Maria |
Aug-2020 | Ramucirumab in elderly patients with hepatocellular carcinoma and elevated alpha-fetoprotein after sorafenib in REACH and REACH-2 | Kudo, Masatoshi; Galle, Peter R.; Llovet i Bayer, Josep Maria; Finn, Richard S.; Vogel, Arndt; Motomura, Kenta; Assenat, Eric; Merle, Philippe; Brandi, Giovanni; Daniele, Bruno; Okusaka, Takuji; Tomášek, Jiří; Borg, Christophe; Dadduzio, Vincenzo; Morimoto, Manabu; Pracht, Marc; Jen, Min-Hua; Widau, Ryan C.; Shinozaki, Kenta; Yoshikawa, Reigetsu; Zhu, Andrew X. |